Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB001158 plus subcutaneous daratumumab vs subcutaneous daratumumab in relapsed or refractory multiple myeloma
2018-004076-35Phase 2Suspended
- Sponsor
- Incyte
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in multiple myeloma (MM) comparing INCB001158 + daratumumab SC with Daratumumab SC (2 arms). Primary endpoints: Safety and tolerability (Phase 1) and Recommended phase 2 dose (RP2D) of INCB001158 in combination with daratumumab SC (Phase 1). Started Jun 2019; status: suspended.
02
Drugs
numidargistatdaratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2018-004076-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004076-35.